Although TaxolⓇ is one of the most successful drugs in current cancer chemotherapy against solid tumors, a major problem is hypersensitivity reactions that arises as a consequence of activation of the complement (C) system, “C activation-related pseudo-allergy”. Most severe hypersenstivity reactions occur within the first few minutes of TaxolⓇ administration, usually after the first or second dose. Here we report a case of a severe hypersensitivity reaction in a 72-year-old man undergoing Genexol-PMⓇ infusion. Hypotension and polymorphic pruritic skin rash appeared 2 hours after the start of Genexol-PMⓇ infusion (with an appropriate premedication). Treating with methylprednisolone, epinephrine and inotropic agents, reduced the hypotension and the skin rash disappeared. We report this case with a review of the literature.
1. Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.Br J Cancer 2004;90:304-5.
2. Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009;102:179-87.
3. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.Clin Cancer Res 2004;10:3708-16.
4. Kim DW, Kim SY, Kim HK, Kim SW, Shin SW, Kim JS, et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2007;18:2009-14.
5. Sendo T, Sakai N, Itoh Y, Ikesue H, Kobayashi H,Hirakawa T, et al. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy.Cancer Chemother Pharmacol 2005;56:91-6.
6. Ring J, Seifert J, Messmer K, Brendel W. Anaphylactoid reactions due to hydroxyethyl starch infusion. Eur Surg Res 1976;8:389-99.
7. Gilbar P, Ridge A. Dexamethasone prophylaxis for paclitaxel hypersensitivity. J Oncol Pharm Pract 2002;8:81-7.
8. Szebeni J. Complement activation-related pseudoallergy:a new class of drug-induced acute immune toxicity.Toxicology 2005;216:106-21.
9. Szebeni J, Alving CR, Savay S, Barenholz Y, Priev A,Danino D, et al. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol 2001;1:721-35.
10. Judge A, McClintock K, Phelps JR, Maclachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther 2006;13:328-37.
11. Szebeni J, Baranyi L, Savay S, Lutz HU, Jelezarova E.Bunger R, et al. The role of complement activation in hypersensitivity to PEGylated liposomal doxorubicin (DoxilⓇ). J Liposome Res 2000;10:467-81.
12. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Wan Kim S, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001;72:191-202.